Indian Journal of Pharmaceutical Sciences, with ISSN 0250-474X and E-ISSN 1998-3743, is a notable publication in the field of Pharmaceutical Sciences, published by the esteemed Indian Pharmaceutical Association. Established in 1978, this journal has been pivotal in disseminating innovative research findings and advancements in pharmaceutical sciences for over four decades. Though no longer covered in Scopus post-2022, its contributions through published works remain relevant to the academic community, ranking in the bottom half of the Scopus percentile for the pharmaceutical category. The journal offers a valuable platform for researchers, professionals, and students to share knowledge and foster collaboration, with a focus on novel methodologies, pharmacological studies, and toxicology. While the journal is not Open Access, it provides essential insights into the evolving landscape of pharmaceutical sciences, making it a key resource for anyone involved in this dynamic field.

CRITICAL REVIEWS IN THERAPEUTIC DRUG CARRIER SYSTEMS is an esteemed academic journal published by BEGELL HOUSE INC, focusing on the innovative field of drug delivery systems and therapeutic carriers. With an ISSN of 0743-4863 and E-ISSN 2162-660X, this journal serves as a pivotal resource for researchers, professionals, and students engaged in pharmaceutical sciences and pharmacology. Spanning from 1984 to 2024, it has sustained its relevance in an evolving landscape, holding a commendable Q2 ranking in both Medicine (miscellaneous) and Pharmaceutical Science, as well as a Q3 ranking in Pharmacology for 2023. The journal is well-regarded for its critical and comprehensive reviews that enhance understanding and drive advancements in therapeutic applications. Access options are variable, providing insights into contemporary practices and innovations that shape drug delivery strategies. With a strong emphasis on interdisciplinary approaches, CRITICAL REVIEWS IN THERAPEUTIC DRUG CARRIER SYSTEMS not only fosters scholarly dialogue but also propels forward the critical field of therapeutic delivery, making it a valuable asset for anyone looking to deepen their knowledge and influence within this dynamic area of study.

Tissue Engineering Part B-Reviews is a premier academic journal published by MARY ANN LIEBERT, INC, focusing on the interdisciplinary field of tissue engineering and regenerative medicine. With an impressive impact factor that places it in the Q1 category across multiple relevant fields—including Biochemistry, Bioengineering, Biomaterials, and Biomedical Engineering—this journal provides a vital platform for researchers and professionals to disseminate cutting-edge findings and comprehensive reviews. Covering a vast scope from 2008 to 2024, the journal is committed to advancing knowledge in the application of engineering principles to biological tissues, making it an indispensable resource for those at the forefront of biomedical innovation. While the journal does not currently offer open access options, its rigorous peer review process ensures high-quality contributions that are essential for academic and practical advancements. The journal's rankings in Scopus reflect its significance, catering to a diverse audience of students, researchers, and practitioners seeking the latest insights in this dynamic field.

The JOURNAL OF PHARMACEUTICAL SCIENCES, published by ELSEVIER SCIENCE INC, stands as a cornerstone in the field of pharmaceutical sciences, offering a platform for innovative research and advancements since its inception in 1961. With an impressive Scopus Rank of #36 out of 183 in the Pharmaceutical Science category, this journal is recognized for its commitment to disseminating high-quality, peer-reviewed studies that significantly contribute to the realms of pharmacology, toxicology, and pharmaceutics. Holding a 2023 Q2 category quartile, it attracts a diverse readership encompassing researchers, industry professionals, and students eager to advance their understanding and expertise. While the journal is not open access, it ensures valuable insights in every issue, making it an essential resource for those dedicated to the evolving landscape of pharmaceutical research. With an impact factor that reflects its relevance and influence, the JOURNAL OF PHARMACEUTICAL SCIENCES continues to shape the discourse in its domain, fostering innovation and collaboration among scholars worldwide.

The Journal of Pharmacy and Bioallied Sciences is a premier open access publication that has been contributing to the fields of Pharmacy, Bioengineering, and Biochemistry since its establishment in India, under the esteemed Wolters Kluwer Medknow Publications. With the ISSN 0976-4879 and E-ISSN 0975-7406, this journal provides a platform for high-quality research articles, reviews, and clinical studies aimed at advancing knowledge and practice in the pharmaceutical and allied sciences. As a reflection of its academic stature, the journal holds a respectable categorization within the third and fourth quartiles in pertinent fields according to the latest metrics, with rankings that place it among prominent emerging research in pharmacology and biochemistry. Researchers and professionals are encouraged to access a wealth of knowledge freely, as the journal has been open access since 2010. The journal not only aims to foster innovative research but also strives to bridge the gap between pharmaceutical sciences and real-world applications, making it an essential resource for students, academics, and industry experts alike.

Expert Opinion on Drug Delivery is a leading journal in the field of pharmaceutical science, published by Taylor & Francis Ltd. With an impressive impact factor and a prestigious Q1 ranking in 2023, it stands out as a vital resource for researchers, professionals, and students dedicated to advancing drug delivery technologies. Established in 2004, the journal has consistently provided a platform for critical insights and expert analyses, bridging the gap between innovation and application in drug delivery systems. Although it currently does not offer Open Access options, the journal's rigorous peer-review process ensures the dissemination of high-quality research that significantly contributes to the fields of pharmacology, toxicology, and pharmaceutics. With its robust ranking of 13th out of 183 in Scopus, the journal continues to foster discourse and collaboration among experts, thereby enhancing the advancement of therapeutic options and improving patient outcomes.

Tissue Engineering and Regenerative Medicine, published by the Korean Tissue Engineering Regenerative Medicine Society, is a distinguished journal focusing on the interdisciplinary fields of tissue engineering, regenerative medicine, and related biomedical innovations. With an ISSN of 1738-2696 and an E-ISSN of 2212-5469, this journal disseminates cutting-edge research and advancements pivotal to developing therapeutic strategies that improve tissue function and repair. As a testament to its scholarly impact, it holds a Q2 ranking in both Biomedical Engineering and Medicine (miscellaneous) categories, reflecting its influence and relevance within the scientific community, particularly with a Scopus rank placing it in the 82nd percentile among similar journals. Although the journal does not offer open access, it provides vital insights and knowledge to researchers, professionals, and students involved in the quest for innovative solutions in medical science and engineering. With its convergence years extending from 2008 to 2024, the journal continues to be an essential platform for the dissemination of high-quality research that drives the field forward.

Pharmaceutics is a prestigious journal published by MDPI, specializing in the field of pharmaceutical sciences. With its Open Access model established in 2010, it promotes the dissemination of cutting-edge research, catering to a global audience of researchers, professionals, and students alike. Based in Switzerland, the journal has rapidly gained recognition, currently holding an impressive Q1 ranking in the pharmaceutical science category for 2023 and achieving a Scopus ranking of #32 out of 183 in the domain of Pharmacology, Toxicology, and Pharmaceutics, placing it in the 82nd percentile. The journal's objectives include advancing knowledge in drug formulation, delivery systems, and therapeutic applications, ensuring that published works contribute significantly to both academic discourse and practical applications in the pharmaceutical industry. As part of its commitment to excellence, Pharmaceutics welcomes high-quality manuscripts that inspire innovation and foster collaboration in this vital field.

Bioengineering & Translational Medicine, published by WILEY, positions itself at the forefront of innovation in the fields of biomedical engineering, biotechnology, and pharmaceutical science. With an impressive impact factor reflected through its top-tier Q1 rankings in multiple categories, the journal serves as a critical platform for disseminating cutting-edge research and stimulating discourse among professionals and scholars since its establishment as an open-access journal in 2016. Key to its mission is facilitating the translation of bioengineering research into tangible medical applications, thereby enhancing healthcare outcomes. With its comprehensive scope, it attracts a diverse readership, including researchers, industry leaders, and students eager to engage with the latest developments in translational medicine. The journal operates under robust access options, ensuring that research is freely available for maximum reach and impact, fostering collaboration and innovation across disciplines worldwide.

The Journal of Pharmaceutical Health Care and Sciences is a premier open access journal published by BMC that aims to advance the field of pharmaceutical sciences by providing high-quality research and comprehensive reviews across various domains including pharmacology, nursing, and healthcare. With an impact factor reflecting its relevance and rigor, the journal has established itself as a significant platform for disseminating knowledge since its inception in 2015. The journal is indexed in Scopus, currently holding a position in the Q3 quartile for medical pharmacology and Q2 quartile for nursing pharmacology, indicating its growing influence and reach in the scientific community. Based in the United Kingdom with a commitment to open access, the Journal of Pharmaceutical Health Care and Sciences ensures that all researchers, professionals, and students have free access to vital research that fosters innovation and improves healthcare outcomes worldwide. With a focus on collaborative and multidisciplinary approaches, the journal invites contributions that align with its objectives of enhancing health care delivery and pharmaceutical practices.